European Network for Hepatitis B and C Surveillance
The European Network for Hepatitis B and C Surveillance comprises the contact points for Hepatitis B and C surveillance that are nominated by the competent bodies for surveillance in EU/EFTA, and includes both epidemiology and virology experts. It aims to improve collaboration, build capacity and facilitate dissemination of information on hepatitis B and C to inform public health policy and planning across Europe.
From 2011 onwards the enhanced surveillance data on hepatitis B and C has been collected annually and is submitted to the European Surveillance System (TESSy) by the national surveillance contact points in the Member States.
• Improve epidemiological data around hepatitis B and C across Europe
• Collection of annual enhanced surveillance data from European countries
• Production of routine surveillance reports
• Publications based around relevant themes
• Development of alternative sources of epidemiological data for hepatitis B and C
- The incidence and routes of transmission of newly diagnosed cases of hepatitis B and C in the general and vulnerable populations;
- the prevalence of chronic hepatitis B and C virus infection to determine burden of infection (and estimate the proportion undiagnosed) in the general and vulnerable populations;
- the proportion of chronic hepatitis B and C cases that are engaged in care (continuum of care);
- the proportion of newly diagnosed chronic hepatitis B and C presenting late.
- The genotype and sequence distributions of newly acquired hepatitis B and hepatitis C viruses to better follow transmission patterns, the emergence of resistance and vaccine escape mutants and potentially more virulent virus strains (priority on hepatitis C infections);
- and describe the proportion of co-infections (HIV/HBV/HCV/HDV)nd describe the proportion of co-infections (HIV/HBV/HCV/HDV);
- the proportion of HCV re-infections (especially among key risk groups with high incidence e.g. PWIDs)
- To provide data to inform, strengthen and improve the development, evaluation and monitoring of national and EU level hepatitis B and C primary prevention and control programmes (e.g. vaccination, harm reduction);
- To monitor the burden of chronic hepatitis B and C infection and their continuum of care to inform, strengthen and improve the development, evaluation and monitoring of secondary prevention programmes (e.g. screening and high quality care pathways);
- To identify emerging population groups at risk (and changes over time) and in need for targeted prevention measures;
- To report on patient safety from healthcare associated infection and healthcare worker safety from occupational transmission;
- To better describe the prevalence of hepatitis in vulnerable populations – for Hepatitis B: especially MSM, IDU, CSW, migrants and for Hepatitis C: especially IDU, prisoners, blood and blood product recipients, migrants;
- To detect and monitor any multi-state outbreaks of viral hepatitis with respect to source, time, person, population and place in order to provide a rationale for public health action.
More on the topic
Hepatitis C is a liver disease caused by infection with the hepatitis C virus (HCV). HCV can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness that lasts only a few weeks to a serious, lifelong illness resulting in cirrhosis and liver cancer.Read more
Hepatitis B is a liver disease that results from infection with the hepatitis B virus (HBV) and is spread through contact with infected body fluids or blood products.Read more
World Hepatitis Day 2018
28 Jul 2018 to 28 Jul 2018 - On the occasion of World Hepatitis Day, ECDC launched online prevalence database for hepatitis B and C which included data mainly based on peer-reviewed cross sectional studies from 2006 onwards.
Preventing blood-borne viruses in prison settings: ECDC and EMCDDA Guidance
23 Jul 2018 - People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use.
Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA
11 Dec 2018 - The scope of this project was to provide an overview of different effective testing strategies for hepatitis B and C and their outcomes in the EU/EEA, covering all relevant population groups and settings.